Business
DNA ImmunoBody Patent Granted in United States
DNA ImmunoBody Patent Granted in United States.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9796I Scancell Holdings Plc 06 June 2014 \n \n\n06 June 2014\n \n \nScancell Holdings Plc\n \nDNA ImmunoBody® Patent Granted in United States\n \n \nScancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in the United States.\n \nThe patent, number 8,742,088, has been granted by The United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody® platform technology. This patent is key for the protection of the Company's pipeline of ImmunoBody® vaccines and follows the grant of counterparts in Australia, China and Japan. \n \nScancell's protein ImmunoBody® patent has already been granted in Australia, Canada, Europe, Japan and the United States. \n \nDr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:\n \n\"We are delighted to have further strengthened our IP portfolio around our proprietary ImmunoBody® platform technology. The United States is a key market for us and this, alongside the recent positive results from the Phase 1/2 trial for our SCIB1 ImmunoBody® in melanoma, demonstrates the strong progress Scancell is making. We look forward to continuing development of our ImmunoBody® platform and advancing our SCIB1 clinical trial, bringing patients one step closer to a new treatment for melanoma.\" \n \n \nFor Further Information: \n \n\n\n\n\nDr Richard Goodfellow, Joint CEO\nProfessor Lindy Durrant, Joint CEO \n\n\nScancell Holdings Plc\nScancell Holdings Plc\n\n\n+ 44 (0) 20 3727 1000\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCamilla Hume/Stephen Keys\n\n\nCenkos Securities\n\n\n+ 44 (0) 20 7397 8900\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMo Noonan/Simon Conway\n\n\nFTI Consulting\n\n\n+ 44 (0) 20 3727 1000\n\n\n\n\n \n \nAbout Scancell \n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouragin...